These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 3529958)

  • 41. Total suppression of ventricular arrhythmias by encainide. Pharmacokinetic and electrocardiographic characteristics.
    Roden DM; Reele SB; Higgins SB; Mayol RF; Gammans RE; Oates JA; Woosley RL
    N Engl J Med; 1980 Apr; 302(16):877-82. PubMed ID: 6767186
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antiarrhythmic drug therapy (Part 2). Benefits and hazards.
    Podrid PJ
    Chest; 1985 Oct; 88(4):618-24. PubMed ID: 3930162
    [No Abstract]   [Full Text] [Related]  

  • 43. Flecainide in the treatment of nonsustained ventricular tachycardia.
    Lal R; Chapman PD; Naccarelli GV; Schechtman KB; Rinkenberger RL; Troup PJ; Kim SS; Dougherty AH; Ruffy R
    Ann Intern Med; 1986 Oct; 105(4):493-8. PubMed ID: 3752754
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Amiodarone-flecainide combination in the treatment of severe ventricular arrhythmia].
    Fontaine G; Frank R; Tonet JL
    Arch Mal Coeur Vaiss; 1984 Nov; 77(12):1421-2. PubMed ID: 6439167
    [No Abstract]   [Full Text] [Related]  

  • 45. Pirmenol in the long-term treatment of chronic ventricular arrhythmias: a placebo-controlled study.
    Toivonen LK; Nieminen MS; Manninen V; Frick MH
    J Cardiovasc Pharmacol; 1986; 8(1):156-60. PubMed ID: 2419679
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia.
    Platia EV; Estes M; Heine DL; Griffith LS; Garan H; Ruskin JN; Reid PR
    Am J Cardiol; 1985 Apr; 55(8):956-62. PubMed ID: 3984883
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exercise-induced ventricular tachycardia as a manifestation of flecainide toxicity.
    Hoffmann A; Wenk M; Follath F
    Int J Cardiol; 1986 Jun; 11(3):353-5. PubMed ID: 3721634
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antiarrhythmic drug efficacy at electrophysiology testing: predictive effectiveness of procainamide and flecainide.
    Wynn J; Torres V; Flowers D; Mizruchi M; Keefe D; Miura D; Somberg J
    Am Heart J; 1986 Apr; 111(4):632-8. PubMed ID: 3953384
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of the efficacy of flecainide acetate in the treatment of ventricular premature contractions.
    Muhiddin KA; Turner P; Hellestrand K; Camm AJ
    Postgrad Med J; 1985 Jun; 61(716):489-96. PubMed ID: 2409543
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of intravenous and oral flecainide on ventricular tachycardia.
    Ward DE; Cheesman M; Dancy M
    Int J Cardiol; 1986 Mar; 10(3):251-62. PubMed ID: 3957470
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group.
    Hopson JR; Buxton AE; Rinkenberger RL; Nademanee K; Heilman JM; Kienzle MG
    Am J Cardiol; 1996 Jan; 77(3):72A-82A. PubMed ID: 8607395
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The treatment of ventricular rhythm disturbances.
    Somberg JC; Miura D; Keefe DL
    Am Heart J; 1986 Jun; 111(6):1162-76. PubMed ID: 2424297
    [No Abstract]   [Full Text] [Related]  

  • 53. Lorcainide. A comparative trial with quinidine gluconate in patients with previously untreated ventricular arrhythmias.
    Falk RH; O'Brien JL
    Chest; 1984 Oct; 86(4):537-40. PubMed ID: 6383741
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Value of flecainide in supraventricular arrhythmias].
    Chouty F; Leclercq JF; Coumel P
    Ann Cardiol Angeiol (Paris); 1986 Apr; 35(4):237-41. PubMed ID: 3740779
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Study of flecainide in the treatment of ventricular arrhythmia].
    Hug C; Koliopoulos N; Tardy C; Errera J; Puech P
    Ann Cardiol Angeiol (Paris); 1983 May; 32(3):161-4. PubMed ID: 6193751
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Comparative study of a slow-release quinidine preparation and flecainide administered in 2 daily doses for the treatment of extrasystole].
    Clémenty J; Castagne D; Dallocchio M; Bricaud H
    Ann Cardiol Angeiol (Paris); 1984 Oct; 33(6):401-5. PubMed ID: 6208841
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Investigational antiarrhythmic drugs for the treatment of ventricular rhythm disturbances.
    Pratt CM; Luck JC; Mann DE; Wyndham CR
    Cardiol Clin; 1984 Feb; 2(1):35-46. PubMed ID: 6443563
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Propafenone and flecainide in the therapy of ventricular arrhythmias].
    Paperini L; Davini A; Lattanzi F; Topi A; Reisenhofer B; Squarcini G; Paci A; Topi PL
    Minerva Cardioangiol; 1995 Oct; 43(10):449-57. PubMed ID: 8819814
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical experience with lorcainide (R 15 889), a new anti-arrhythmic drug.
    Kesteloot H; Stroobandt R
    Arch Int Pharmacodyn Ther; 1977 Dec; 230(2):225-34. PubMed ID: 603318
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
    Cardiac Arrhythmia Pilot Study (CAPS) Investigators
    Am J Cardiol; 1988 Mar; 61(8):501-9. PubMed ID: 2894169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.